Business Wire

Cedo Commits to Climate Neutrality By 2030

27.7.2021 10:00:00 EEST | Business Wire | Press release

Share

Cedo, one of Europe’s largest manufacturers of household waste bags made with recycled plastics, has made its first major leap towards becoming a climate neutral business, powering its UK factory in Telford and offices in Paris and Mönchengladbach with 100 per cent renewable energy. Its UK business, based in Shropshire, has also achieved its target of sending zero manufacturing waste to landfill.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005178/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cedo’s UK business and offices in Paris and Mönchengladbach are now all powered by 100 per cent renewable energy (Photo: Business Wire)

More than 23 per cent of Cedo’s global operations now use 100 per cent renewable energy, with suppliers including green energy provider Total and PGE S.A in Poland. Cedo’s remaining factories in Vietnam, Poland and the Netherlands are also on target to achieve climate neutrality over the next few years.

“Cedo’s aim is to become a climate neutral business worldwide by 2030. By increasing our use of renewable energy year-on-year while focusing our efforts on achieving zero manufacturing waste to landfill, we are making rapid progress towards our goal,” said Rik De Vos, CEO of Cedo. “Our next ambition is to continue to pursue a more circular approach in our stewardship of raw materials, while creating a sustainable business that is no longer reliant on fossil fuel-based virgin polymers.

“In the very near future every Cedo non-food product will be fully recycled and recyclable. We believe that keeping our homes clean, safe and tidy in an environmentally friendly way should be as simple as putting out the bins,” said De Vos.

Established in 1965, Cedo is one of the world’s leading plastics recycling businesses, specialising in the recycling of post-consumer household packaging waste such as plastic packaging and clingfilm. Every year, the business uses more than 80,000 tons of recycled plastic to make over 4 billion refuse sacks and bin liners from factories based in Poland, the Netherlands, Vietnam and the UK, operating one of the largest flexible plastic film recycling centres in Europe.

Cedo products from bin liners to food wrap and latex gloves can be found in supermarkets and retailers in 34 countries. In the UK, 93% of the plastic used by Cedo to manufacture non-food products is from recycled sources.

As we approach Earth Overshoot Day on 29 July, Cedo is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.

- Ends –

About Cedo

Established in 1965, Cedo is one of Europe's largest and most sustainable suppliers of refuse sacks made from recycled plastics, as well as other consumer household products designed to protect and store food. For more than thirty years it has led the development of recycling mixed plastic film recovered from households to give more plastic a second life, creating 100% recycled and 100% recyclable products designed to keep European households, workplaces and leisure spaces clean, healthy and safe.

As founding signatories to both the Ellen MacArthur Foundation’s New Plastics Economy Global Commitments and the European Plastics Pact, Cedo is working with partners including NGO The Plastic Bank to create new solutions and interventions to address the challenges of building a new plastics economy.

For two years, Cedo has been recognised by the Sunday Times top track 250 (fast growing medium sized privately owned business). By 2030 the business will be climate neutral across its global operations.

For more information please visit cedo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information and to request visuals or interviews:
Miki Haines-Sanger
Golden Goose Communications
+44 7 900 690 574
miki@goldengoosepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye